CDK4 and malignant peripheral nerve sheath tumor: Our mouse MPNST model findings predicted that CDK4/6-MEK inhibitor therapy would sensitize MPNSTs to ICB therapy, not only because of increased plasma cells but also given the upregulation of PD-L1 in drug resistant MPNSTs.